Survey for CLL patients having taken Venetoclax or Acalabrutinib

[CLL_Canada_Group]

CLL/SLL Patient Survey

If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey:

Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) monotherapy for treatment of relapsed/refractory CLL/SLL

Lymphoma Canada and CLL Patient Advocacy Group (CLLPAG) are preparing submissions for the pan­Canadian Oncology Drug Review (pCODR) so that CLL/SLL patients in Canada can gain access to these therapies.

You can help by completing our survey, which will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs. You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE NEW TREATMENTS IN CANADA.

The survey will be open until midnight Pacific Time on Friday, February 7th, 2020 and should only take 10 minutes of your time.

You may access the survey by clicking the link below.

surveymonkey.com/r/CLLCAN2020

Thank you!

Rebecca Drotos